Hepatitis A through E

Journal of Intravenous Nursing

Volumn 21, Issue 5, 1998, Pages 286-290

  Moyer, Linda A ^a   Mast, Eric E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS ANTIBODY; HEPATITIS ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; HEPATITIS DELTA ANTIGEN; HEPATITIS VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERFERON; RIBAVIRIN;

DELTA AGENT HEPATITIS; ENDEMIC DISEASE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; REVIEW; SERODIAGNOSIS; UNITED STATES; VIRUS HEPATITIS; VIRUS TRANSMISSION;

ENDEMIC DISEASES; HEPATITIS, VIRAL, HUMAN; HUMANS; MASS SCREENING; RISK FACTORS; UNITED STATES; VACCINATION;

EID: 0031685318     PISSN: 08965846     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Hepatitis Surveillance Report No. 56. Atlanta: Centers for Disease Control and Prevention, 1995.
2. Liaw YF, Yang CY, Chu CM, et al. Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak. Infection 1986;14:156-8.
3. Stapleton JT. Host immune response to hepatitis A virus. J Infect Dis 1995;171(Suppl 1):S9-14.
4. Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-6.
5. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(No. RR-15):1-30.
6. Papaevangelou GJ, Roumeliotou-Karayannis AJ, Contoyannis PC. The risk of nosocomial hepatitis A and B virus infections from patients under care without isolation precaution. J Med Virol 1981;7: 143-8.
7. Kashiwagi S, Hayashi J, Ikematsu H, et al. Prevalence of immunologic markers of hepatitis A and B infection in hospital personnel in Miyazaki Prefecture, Japan. Am J Epidemiol 1985;122:960-9.
8. Gibas A, Blewett DR, Schoenfield DA, et al. Prevalence and incidence of viral hepatitis in health workers in the prehepatitis B vaccination era. Am J Epidemiol 1992;136:603-10.
9. Alter MJ. Nosocomial hepatitis A infection: can we wash our hands of it? Pediatr Infect Dis 1984;3:294-5.
10. Centers for Disease Control and Prevention. Enterically transmitted non-A, non-B hepatitis-Mexico. MMWR 1987;36:597-602.
11. Bellabbes EH, Bourguermouh A, Benatallah A, et al. Epidemic non-A, non-B hepatitis in Algeria: strong evidence for its spreading by water. J Med Virol 1985;16:257-63.
12. Centers for Disease Control and Prevention. Hepatitis E among U.S. travelers, 1989-1992. MMWR 1993;42:1-4.
13. Mast EE, Kuramoto IK, Favorov MO. Prevalence of and risk factors for antibody to hepatitis E virus seroreactivity among blood donors in northern California. J Infect Dis 1997;176:34-49.
14. Mast EE, Alter MJ. Epidemiology of viral hepatitis: an overview. Seminars in Virology 1993;4:273-83.
15. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(No. RR-13):1-25.
16. Centers for Disease Control and Prevention. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990;39(no. RR-2):1-27.
17. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 1990;263:1218-22.
18. Denes AE, Sith JL, Maynard JE, et al. Hepatitis B infection in physicians: results of a nationwide sero-epidemiologic survey. JAMA 1978;239:210-2.
19. Dienstag JL, Ryan FM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982;115:26-39.
20. Hadler SC, Doto IL, Maynard JE, et al. Occupational risk of hepatitis B infection in hospital workers. Infect Control Hosp Epidemiol 1985;6:24-31.
21. Segal HE, Llewellyn CH, Irwin G, et al. Hepatitis B antigen and antibody in the US Army: prevalence in health care personnel. Am J Public Health 1976;66:667-71.
22. Grady GF, Lee VA, Prince Am, et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978;138:625-38.
23. Seeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needlestick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978;88:285-93.
24. Shikata T, Karasawa T, Ave K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977;136:571-6.
25. Centers for Disease Control and Prevention. Update: universal precautions for prevention of transmission of human immunodeficiency virus and hepatitis B virus and other blood borne pathogens in health-care settings. MMWR 1988;37:377-88.
26. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257:2612-6.
27. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-41.
28. Poovorawan Y, Sanpavat S, Pongpuniert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989;261:3278-81.
29. Francis DP, Hadler SC, Thompson SE, et al. Prevention of hepatitis B with vaccine: report from the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-6.
30. U.S. Department of Labor, Occupational Safety and Health Administration occupational exposure to blood borne pathogens: final rule. Federal Register 1991;56:64004-182.
31. Mahoney FJ, Stewart K, Hanxian H. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997;157:2601-5.
32. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
33. Aach RD, Stevens CD, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first-and second-generation assays. N Engl J Med 1991;325:1325-9.
34. Alter HJ, Jett BW, Polito AJ, et al. Analysis of the role of hepatitis C virus in transfusion-associated hepatitis. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins, 1991:396-402.
35. Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B posttransfusion hepatitis: looking back in the second decade. Ann Intern Med 1993;119:110-5.
36. Wright TL. Etiology of fulminant hepatic failure: is another virus involved? Gastroenterology 1993;104:640-53.
37. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995;123:330-7.
38. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
39. Esteban JI, Lopez-Talvera J, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-9.
40. McQuillan G, Alter M, Moyer L, et al. A population based serologic study of hepatitis C virus infection in the United States [abstract]. Proceedings of the IX International Symposium on Viral Hepatitis and Liver Disease, Rome 1996;8:267-70.
41. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-13.
42. DeMedina M, Schiff ER. Hepatitis C: diagnostic assays. Semin Liver Dis 1995;15:33-40.
43. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
44. Kleinman S, Alter H, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992;32:805-13.
45. Mimms L, Vallari D, Ducharme L, et al. Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions. Lancet 1990;336:1590-1.
46. National Institutes of Health. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26:2S-10S.
47. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
48. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173:822-8.
49. Centers for Disease Control and Prevention. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991;40(RR-4):1-17.
50. Rizzetto M. The delta agent. Hepatology 1983;3:729.
51. Caredda F, Antinori S, Re T, et al. Course and prognosis of acute HDV infection. In: Rizzetto M, Gerin JL, Purcell RH, eds. Hepatitis Delta Virus and Its Infection. New York: Alan R. Liss, 1987:267-76.